Michel Fabbro
0000-0003-1910-4777
CANCER INSTITUTE MONTPELLIER
10 papers found
Refreshing results…
Differential Sensitivity of Germline and Somatic BRCA Variants to PARP Inhibitor in High-Grade Serous Ovarian Cancer
Ad hocAnalysis of the Phase III ENGOT-OV16/NOVA Study: Niraparib Efficacy in GermlineBRCAWild-type Recurrent Ovarian Cancer with Homologous Recombination Repair Defects
Reduced-dose WBRT as consolidation treatment for patients with primary CNS lymphoma: an LOC network study
Investigation of Molecular Features Involved in Clinical Responses and Survival in Advanced Endometrial Carcinoma Treated by Hormone Therapy
Genomic Instability Is Defined by Specific Tumor Microenvironment in Ovarian Cancer: A Subgroup Analysis of AGO OVAR 12 Trial
Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovarian Cancer, Part 1: Technical Considerations
Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovarian Cancer Part 2: Medical Perspectives
Conditional Probability of Survival and Prognostic Factors in Long-Term Survivors of High-Grade Serous Ovarian Cancer
CA-125 ELIMination rate constant K (KELIM) Is A Marker Of Chemosensitivity In Patients With Ovarian Cancer: Results from the Phase II CHIVA trial
Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial
Missing publications? Search for publications with a matching author name.